ID   HEM3_HUMAN              Reviewed;         361 AA.
AC   P08397; A8K2L0; G3V1P4; G5EA58; P08396; Q16012;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Porphobilinogen deaminase;
DE            Short=PBG-D;
DE            EC=2.5.1.61;
DE   AltName: Full=Hydroxymethylbilane synthase;
DE            Short=HMBS;
DE   AltName: Full=Pre-uroporphyrinogen synthase;
GN   Name=HMBS; Synonyms=PBGD, UPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2875434; DOI=10.1093/nar/14.15.5955;
RA   Raich N., Romeo P.-H., Dubart A., Beaupain D., Cohen-Solal M.,
RA   Goossens M.;
RT   "Molecular cloning and complete primary sequence of human erythrocyte
RT   porphobilinogen deaminase.";
RL   Nucleic Acids Res. 14:5955-5968(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3816774; DOI=10.1111/j.1432-1033.1987.tb10548.x;
RA   Grandchamp B., de Verneuil H., Beaumont C., Chretien S., Walter O.,
RA   Nordmann Y.;
RT   "Tissue-specific expression of porphobilinogen deaminase. Two
RT   isoenzymes from a single gene.";
RL   Eur. J. Biochem. 162:105-110(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7916736; DOI=10.1006/geno.1993.1005;
RA   Yoo H.-W., Warner C.A., Chen C.-H., Desnick R.J.;
RT   "Hydroxymethylbilane synthase: complete genomic sequence and
RT   amplifiable polymorphisms in the human gene.";
RL   Genomics 15:21-29(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-53, AND TISSUE SPECIFICITY.
RX   PubMed=3422427; DOI=10.1073/pnas.85.1.6;
RA   Chretien S., Dubart A., Beaupain D., Raich N., Grandchamp B., Rosa J.,
RA   Goossens M., Romeo P.-H.;
RT   "Alternative transcription and splicing of the human porphobilinogen
RT   deaminase gene result either in tissue-specific or in housekeeping
RT   expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6-10(1988).
RN   [9]
RP   PROTEIN SEQUENCE OF 18-36 (ISOFORM 2).
RX   PubMed=2609111; DOI=10.3109/00365518909091544;
RA   Lannfelt L., Wetterberg L., Lilius L., Thunell S., Joernvall H.,
RA   Pavlu B., Wielburski A., Gellerfors P.;
RT   "Porphobilinogen deaminase in human erythrocytes: purification of two
RT   forms with apparent molecular weights of 40 kDa and 42 kDa.";
RL   Scand. J. Clin. Lab. Invest. 49:677-684(1989).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15; SER-69 AND SER-147,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS).
RX   PubMed=19207107; DOI=10.1042/BJ20082077;
RA   Gill R., Kolstoe S.E., Mohammed F., Al D-Bass A., Mosely J.E.,
RA   Sarwar M., Cooper J.B., Wood S.P., Shoolingin-Jordan P.M.;
RT   "Structure of human porphobilinogen deaminase at 2.8 A: the molecular
RT   basis of acute intermittent porphyria.";
RL   Biochem. J. 420:17-25(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS), AND PROSTHETIC GROUP AT
RP   CYS-261.
RX   PubMed=18936296; DOI=10.1096/fj.08-115469;
RA   Song G., Li Y., Cheng C., Zhao Y., Gao A., Zhang R., Joachimiak A.,
RA   Shaw N., Liu Z.J.;
RT   "Structural insight into acute intermittent porphyria.";
RL   FASEB J. 23:396-404(2009).
RN   [18]
RP   VARIANTS AIP GLN-167 AND GLN-173.
RX   PubMed=2243128; DOI=10.1172/JCI114869;
RA   Delfau M.H., Picat C., de Rooij F.W.M., Hamer K., Bogard M.,
RA   Wilson J.H.P., Deybach J.-C., Nordmann Y., Grandchamp B.;
RT   "Two different point G to A mutations in exon 10 of the
RT   porphobilinogen deaminase gene are responsible for acute intermittent
RT   porphyria.";
RL   J. Clin. Invest. 86:1511-1516(1990).
RN   [19]
RP   VARIANTS AIP GLN-149 AND ARG-245.
RX   PubMed=1714233;
RA   Delfau M.H., Picat C., de Rooij F.W.M., Voortman G., Deybach J.-C.,
RA   Nordmann Y., Grandchamp B.;
RT   "Molecular heterogeneity of acute intermittent porphyria:
RT   identification of four additional mutations resulting in the CRIM-
RT   negative subtype of the disease.";
RL   Am. J. Hum. Genet. 49:421-428(1991).
RN   [20]
RP   VARIANT AIP TRP-167.
RX   PubMed=1496994;
RA   Gu X.-F., de Rooij F.W.M., Voortman G., Te Velde K., Nordmann Y.,
RA   Grandchamp B.;
RT   "High frequency of mutations in exon 10 of the porphobilinogen
RT   deaminase gene in patients with a CRIM-positive subtype of acute
RT   intermittent porphyria.";
RL   Am. J. Hum. Genet. 51:660-665(1992).
RN   [21]
RP   VARIANTS AIP LYS-34; GLN-167; ARG-177 AND ASN-256.
RX   PubMed=1427766; DOI=10.1007/BF00210738;
RA   Mgone C.S., Lanyon W.G., Moore M.R., Connor J.M.;
RT   "Detection of seven point mutations in the porphobilinogen deaminase
RT   gene in patients with acute intermittent porphyria, by direct
RT   sequencing of in vitro amplified cDNA.";
RL   Hum. Genet. 90:12-16(1992).
RN   [22]
RP   VARIANTS AIP TRP-167 AND GLN-173.
RX   PubMed=1301948; DOI=10.1002/humu.1380010508;
RA   Kauppinen R., Peltonen L., Pihlaja H., Mustajoki P.;
RT   "CRIM-positive mutations of acute intermittent porphyria in Finland.";
RL   Hum. Mutat. 1:392-396(1992).
RN   [23]
RP   VARIANTS AIP ARG-247; THR-252 AND VAL-252.
RX   PubMed=8262523; DOI=10.1007/BF00420949;
RA   Mgone C.S., Lanyon W.G., Moore M.R., Louie G.V., Connor J.M.;
RT   "Detection of a high mutation frequency in exon 12 of the
RT   porphobilinogen deaminase gene in patients with acute intermittent
RT   porphyria.";
RL   Hum. Genet. 92:619-622(1993).
RN   [24]
RP   VARIANT AIP HIS-26.
RX   PubMed=8401516; DOI=10.1093/hmg/2.8.1315;
RA   Llewellyn D.H., Whatley S.D., Elder G.H.;
RT   "Acute intermittent porphyria caused by an arginine to histidine
RT   substitution (R26H) in the cofactor-binding cleft of porphobilinogen
RT   deaminase.";
RL   Hum. Mol. Genet. 2:1315-1316(1993).
RN   [25]
RP   VARIANT AIP ARG-111.
RX   PubMed=8268934; DOI=10.1093/hmg/2.10.1735;
RA   Gu X.-F., de Rooij F.W.M., de Baar E., Bruyland M., Lissens W.,
RA   Nordmann Y., Grandchamp B.;
RT   "Two novel mutations of the porphobilinogen deaminase gene in acute
RT   intermittent porphyria.";
RL   Hum. Mol. Genet. 2:1735-1736(1993).
RN   [26]
RP   VARIANTS AIP THR-31; SER-55; LEU-149; LYS-223 AND LYS-250.
RX   PubMed=8270254; DOI=10.1007/BF00218912;
RA   Gu X.-F., de Rooij F.W.M., Voortman G., Te Velde K., Deybach J.-C.,
RA   Nordmann Y., Grandchamp B.;
RT   "Detection of eleven mutations causing acute intermittent porphyria
RT   using denaturing gradient gel electrophoresis.";
RL   Hum. Genet. 93:47-52(1994).
RN   [27]
RP   VARIANT AIP TRP-201.
RX   PubMed=8270256; DOI=10.1007/BF00218914;
RA   Lundin G., Wedell A., Thunell S., Anvret M.;
RT   "Two new mutations in the porphobilinogen deaminase gene and a
RT   screening method using PCR amplification of specific alleles.";
RL   Hum. Genet. 93:59-62(1994).
RN   [28]
RP   VARIANTS AIP GLN-116; TRP-173; ARG-177; ILE-269 AND ARG-274.
RX   PubMed=8081367; DOI=10.1093/hmg/3.5.809;
RA   Mgone C.S., Lanyon W.G., Moore M.R., Louie G.V., Connor J.M.;
RT   "Identification of five novel mutations in the porphobilinogen
RT   deaminase gene.";
RL   Hum. Mol. Genet. 3:809-811(1994).
RN   [29]
RP   REVIEW ON AIP VARIANTS.
RX   PubMed=7866402; DOI=10.1002/humu.1380040403;
RA   Astrin K.N., Desnick R.J.;
RT   "Molecular basis of acute intermittent porphyria: mutations and
RT   polymorphisms in the human hydroxymethylbilane synthase gene.";
RL   Hum. Mutat. 4:243-252(1994).
RN   [30]
RP   VARIANTS AIP PHE-93; TRP-116; TRP-201 AND PHE-247.
RX   PubMed=7962538; DOI=10.1172/JCI117543;
RA   Chen C.-H., Astrin K.H., Lee G., Anderson K.E., Desnick R.J.;
RT   "Acute intermittent porphyria: identification and expression of exonic
RT   mutations in the hydroxymethylbilane synthase gene. An initiation
RT   codon missense mutation in the housekeeping transcript causes 'variant
RT   acute intermittent porphyria' with normal expression of the erythroid-
RT   specific enzyme.";
RL   J. Clin. Invest. 94:1927-1937(1994).
RN   [31]
RP   VARIANTS AIP.
RX   PubMed=7757070; DOI=10.1093/hmg/4.2.215;
RA   Kauppinen R., Mustajoki S., Pihlaja H., Peltonen L., Mustajoki P.;
RT   "Acute intermittent porphyria in Finland: 19 mutations in the
RT   porphobilinogen deaminase gene.";
RL   Hum. Mol. Genet. 4:215-222(1995).
RN   [32]
RP   VARIANTS AIP LEU-119 AND ALA-250.
RX   PubMed=8825929; DOI=10.1136/jmg.32.12.979;
RA   Lundin G., Hashemi J., Floderus Y., Thunell S., Sagen E., Laegreid A.,
RA   Wassif W., Peters T., Anvret M.;
RT   "Four mutations in the porphobilinogen deaminase gene in patients with
RT   acute intermittent porphyria.";
RL   J. Med. Genet. 32:979-981(1995).
RN   [33]
RP   VARIANTS AIP.
RX   PubMed=9199558; DOI=10.1086/515455;
RA   Puy H., Deybach J.-C., Lamoril J., Robreau A.-M., Da Silva V.,
RA   Gouya L., Grandchamp B., Nordmann Y.;
RT   "Molecular epidemiology and diagnosis of PBG deaminase gene defects in
RT   acute intermittent porphyria.";
RL   Am. J. Hum. Genet. 60:1373-1383(1997).
RN   [34]
RP   VARIANTS AIP TRP-116; LEU-119; GLN-167; TRP-167; TRP-173; TRP-201 AND
RP   ASP-216.
RX   PubMed=9225970; DOI=10.1007/s004390050466;
RA   Lundin G., Lee J.-S., Thunell S., Anvret M.;
RT   "Genetic investigation of the porphobilinogen deaminase gene in
RT   Swedish acute intermittent porphyria families.";
RL   Hum. Genet. 100:63-66(1997).
RN   [35]
RP   VARIANTS AIP MET-222 AND PRO-278.
RX   PubMed=9654202; DOI=10.1007/s004390050737;
RA   Mustajoki S., Pihlaja H., Ahola H., Petersen N.E., Mustajoki P.,
RA   Kauppinen R.;
RT   "Three splicing defects, an insertion, and two missense mutations
RT   responsible for acute intermittent porphyria.";
RL   Hum. Genet. 102:541-548(1998).
RN   [36]
RP   VARIANT AIP CYS-22.
RX   PubMed=9463797; DOI=10.1159/000022777;
RA   Ong P.M., Lanyon W.G., Hift R.J., Halkett J., Cramp C.E., Moore M.R.,
RA   Connor J.M.;
RT   "Identification of two novel mutations in the hydroxymethylbilane
RT   synthase gene in three patients from two unrelated families with acute
RT   intermittent porphyria.";
RL   Hum. Hered. 48:24-29(1998).
RN   [37]
RP   VARIANTS AIP PRO-34; ARG-111; TRP-173; TRP-201; 329-LEU--GLN-332 DEL
RP   AND SER-335.
RX   PubMed=10494093;
RX   DOI=10.1002/(SICI)1096-8628(19991008)86:4<366::AID-AJMG11>3.0.CO;2-#;
RA   De Siervi A., Rossetti M.V., Parera V.E., Astrin K.H., Aizencang G.I.,
RA   Glass I.A., Batlle A.M.C., Desnick R.J.;
RT   "Identification and characterization of hydroxymethylbilane synthase
RT   mutations causing acute intermittent porphyria: evidence for an
RT   ancestral founder of the common G111R mutation.";
RL   Am. J. Med. Genet. 86:366-375(1999).
RN   [38]
RP   VARIANTS AIP CYS-22; CYS-26; HIS-26; PRO-31; SER-42; ASN-61; ARG-85;
RP   GLY-90; ARG-111; GLN-173; TRP-173; ARG-177; CYS-195; ASP-219; ARG-247
RP   AND ILE-269.
RX   PubMed=10453740; DOI=10.1007/s004390050995;
RA   Whatley S.D., Woolf J.R., Elder G.H.;
RT   "Comparison of complementary and genomic DNA sequencing for the
RT   detection of mutations in the HMBS gene in British patients with acute
RT   intermittent porphyria: identification of 25 novel mutations.";
RL   Hum. Genet. 104:505-510(1999).
RN   [39]
RP   VARIANT AIP ALA-152 DEL.
RX   PubMed=10502788;
RX   DOI=10.1002/(SICI)1098-1004(199910)14:4<355::AID-HUMU19>3.0.CO;2-T;
RA   De Siervi A., Mendez M., Parera V.E., Varela L., Batlle A.M.C.,
RA   Rossetti M.V.;
RT   "Acute intermittent porphyria: characterization of two novel mutations
RT   in the porphobilinogen deaminase gene, one amino acid deletion (453-
RT   455delAGC) and one splicing acceptor site mutation (IVS8-1G>T).";
RL   Hum. Mutat. 14:355-355(1999).
RN   [40]
RP   VARIANTS AIP CYS-26 AND LEU-202.
RX   PubMed=10657149; DOI=10.1006/mcpr.1999.0276;
RA   Gross U., Puy H., Doss M., Robreau A.-M., Nordmann Y., Doss M.O.,
RA   Deybach J.-C.;
RT   "New mutations of the hydroxymethylbilane synthase gene in German
RT   patients with acute intermittent porphyria.";
RL   Mol. Cell. Probes 13:443-447(1999).
RN   [41]
RP   VARIANTS AIP ARG-111; TRP-116; TRP-167; TRP-173 AND VAL-212, AND
RP   CHARACTERIZATION OF VARIANT AIP VAL-212.
RX   PubMed=10602775;
RA   Solis C., Lopez-Echaniz I., Sefarty-Graneda D., Astrin K.H.,
RA   Desnick R.J.;
RT   "Identification and expression of mutations in the hydroxymethylbilane
RT   synthase gene causing acute intermittent porphyria (AIP).";
RL   Mol. Med. 5:664-671(1999).
RN   [42]
RP   VARIANTS AIP PRO-78; GLY-80; ARG-111 AND TRP-173.
RX   PubMed=11399210; DOI=10.1097/00125817-200009000-00004;
RA   Ramdall R.B., Cunha L., Astrin K.H., Katz D.R., Anderson K.E.,
RA   Glucksman M., Bottomley S.S., Desnick R.J.;
RT   "Acute intermittent porphyria: novel missense mutations in the human
RT   hydroxymethylbilane synthase gene.";
RL   Genet. Med. 2:290-295(2000).
RN   [43]
RP   VARIANTS AIP TRP-116 AND GLY-270.
RX   PubMed=11030413; DOI=10.1007/s004390000323;
RA   Robreau-Fraolini A.M., Puy H., Aquaron C., Bogard C., Traore M.,
RA   Nordmann Y., Aquaron R., Deybach J.-C.;
RT   "Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic
RT   groups: mutations causing acute intermittent porphyria and specific
RT   intragenic polymorphisms.";
RL   Hum. Genet. 107:150-159(2000).
RN   [44]
RP   VARIANT AIP LEU-217.
RX   PubMed=10782018; DOI=10.1159/000022924;
RA   Schneider-Yin X., Bogard C., Rufenacht U.B., Puy H., Nordmann Y.,
RA   Minder E.I., Deybach J.-C.;
RT   "Identification of a prevalent nonsense mutation (W283X) and two novel
RT   mutations in the porphobilinogen deaminase gene of Swiss patients with
RT   acute intermittent porphyria.";
RL   Hum. Hered. 50:247-250(2000).
RN   [45]
RP   VARIANTS AIP MET-35; ARG-111 AND GLY-281 DEL.
RX   PubMed=11013452;
RX   DOI=10.1002/1098-1004(200010)16:4<373::AID-HUMU14>3.0.CO;2-A;
RA   De Siervi A., Weiss Cadiz D.E., Parera V.E., Batlle A.M.C.,
RA   Rossetti M.V.;
RT   "Identification and characterization of two novel mutations that
RT   produce acute intermittent porphyria: a 3-base deletion (841-
RT   843delGGA) and a missense mutation (T35M).";
RL   Hum. Mutat. 16:373-373(2000).
RN   [46]
RP   ERRATUM, AND VARIANT AIP ASN-99.
RA   Martinez di Montemuros F., Di Pierro E., Fiorelli G., Cappellini M.D.;
RL   Hum. Genet. 109:241-241(2001).
RN   [47]
RP   VARIANTS AIP ILE-18; PHE-96; HIS-99; GLY-122; PRO-254 AND TYR-261.
RX   PubMed=12406973;
RA   Kauppinen R., von und zu Fraunberg M.;
RT   "Molecular and biochemical studies of acute intermittent porphyria in
RT   196 patients and their families.";
RL   Clin. Chem. 48:1891-1900(2002).
RN   [48]
RP   VARIANTS AIP CYS-26; HIS-26; VAL-86; PRO-92; GLY-99; ARG-111; THR-113;
RP   GLN-173; ASN-178; GLN-225; GLY-225; TYR-256; ASP-260 AND PRO-343.
RX   PubMed=12372055; DOI=10.1034/j.1399-0004.2002.620406.x;
RA   Floderus Y., Shoolingin-Jordan P.M., Harper P.;
RT   "Acute intermittent porphyria in Sweden. Molecular, functional and
RT   clinical consequences of some new mutations found in the
RT   porphobilinogen deaminase gene.";
RL   Clin. Genet. 62:288-297(2002).
RN   [49]
RP   VARIANTS AIP HIS-26; TYR-61; VAL-93 DEL; ARG-111; GLN-173 AND ASP-335.
RX   PubMed=11857754; DOI=10.1002/humu.9020;
RA   Gregor A., Schneider-Yin X., Szlendak U., Wettstein A., Lipniacka A.,
RA   Ruefenacht U.B., Minder E.I.;
RT   "Molecular study of the hydroxymethylbilane synthase gene (HMBS) among
RT   Polish patients with acute intermittent porphyria.";
RL   Hum. Mutat. 19:310-310(2002).
RN   [50]
RP   CHARACTERIZATION OF VARIANTS AIP GLY-99; GLN-149; GLN-167 AND GLN-173.
RX   PubMed=12773194; DOI=10.1042/BST0310731;
RA   Shoolingin-Jordan P.M., Al-Dbass A., McNeill L.A., Sarwar M.,
RA   Butler D.;
RT   "Human porphobilinogen deaminase mutations in the investigation of the
RT   mechanism of dipyrromethane cofactor assembly and tetrapyrrole
RT   formation.";
RL   Biochem. Soc. Trans. 31:731-735(2003).
RN   [51]
RP   VARIANTS AIP GLU-215 AND PRO-238.
RX   PubMed=14757946; DOI=10.1155/2003/384971;
RA   Tjensvoll K., Bruland O., Floderus Y., Skadberg O., Sandberg S.,
RA   Apold J.;
RT   "Haplotype analysis of Norwegian and Swedish patients with acute
RT   intermittent porphyria (AIP): Extreme haplotype heterogeneity for the
RT   mutation R116W.";
RL   Dis. Markers 19:41-46(2003).
RN   [52]
RP   VARIANTS AIP ARG-34; SER-236 AND PRO-244.
RX   PubMed=14669009; DOI=10.1007/s00439-003-1059-5;
RA   Gouya L., Puy H., Robreau A.-M., Lyoumi S., Lamoril J., Da Silva V.,
RA   Grandchamp B., Deybach J.-C.;
RT   "Modulation of penetrance by the wild-type allele in dominantly
RT   inherited erythropoietic protoporphyria and acute hepatic
RT   porphyrias.";
RL   Hum. Genet. 114:256-262(2004).
RN   [53]
RP   VARIANT AIP PRO-81.
RX   PubMed=14970743; DOI=10.1023/B:BOLI.0000016613.75677.05;
RA   Hessels J., Voortman G., van der Wagen A., van der Elzen C.,
RA   Scheffer H., Zuijderhoudt F.M.J.;
RT   "Homozygous acute intermittent porphyria in a 7-year-old boy with
RT   massive excretions of porphyrins and porphyrin precursors.";
RL   J. Inherit. Metab. Dis. 27:19-27(2004).
RN   [54]
RP   VARIANTS AIP ARG-111 AND GLN-173.
RX   PubMed=15669678; DOI=10.1023/B:BOLI.0000042936.20691.ad;
RA   Schneider-Yin X., Hergersberg M., Schuurmans M.M., Gregor A.,
RA   Minder E.I.;
RT   "Mutation hotspots in the human porphobilinogen deaminase gene:
RT   recurrent mutations G111R and R173Q occurring at CpG motifs.";
RL   J. Inherit. Metab. Dis. 27:625-631(2004).
RN   [55]
RP   VARIANTS AIP HIS-26; TRP-173; CYS-195; ARG-247 AND ALA-250, AND
RP   CHARACTERIZATION OF VARIANTS AIP HIS-26; TRP-173; CYS-195; ARG-247 AND
RP   ALA-250.
RX   PubMed=16211556; DOI=10.1002/humu.9381;
RA   Pischik E., Mehtaelae S., Kauppinen R.;
RT   "Nine mutations including three novel mutations among Russian patients
RT   with acute intermittent porphyria.";
RL   Hum. Mutat. 26:496-496(2005).
RN   [56]
RP   VARIANTS AIP ILE-59 AND MET-215, AND CHARACTERIZATION OF VARIANTS AIP
RP   ILE-59 AND MET-215.
RX   PubMed=18406650; DOI=10.1016/j.ymgme.2008.03.001;
RA   Schneider-Yin X., Ulbrichova D., Mamet R., Martasek P., Marohnic C.C.,
RA   Goren A., Minder E.I., Schoenfeld N.;
RT   "Characterization of two missense variants in the hydroxymethylbilane
RT   synthase gene in the Israeli population, which differ in their
RT   associations with acute intermittent porphyria.";
RL   Mol. Genet. Metab. 94:343-346(2008).
RN   [57]
RP   VARIANT AIP PRO-32, AND CHARACTERIZATION OF VARIANTS AIP PRO-32 AND
RP   ASN-178.
RX   PubMed=19138865; DOI=10.1016/j.bcmd.2008.11.001;
RA   Ulbrichova D., Schneider-Yin X., Mamet R., Saudek V., Martasek P.,
RA   Minder E.I., Schoenfeld N.;
RT   "Correlation between biochemical findings, structural and enzymatic
RT   abnormalities in mutated HMBS identified in six Israeli families with
RT   acute intermittent porphyria.";
RL   Blood Cells Mol. Dis. 42:167-173(2009).
RN   [58]
RP   VARIANTS AIP CYS-26; HIS-26; GLN-173; LYS-204 AND ASP-250, AND
RP   CHARACTERIZATION OF VARIANTS AIP CYS-26; HIS-26; GLN-173; LYS-204 AND
RP   ASP-250.
RX   PubMed=19292878; DOI=10.1111/j.1742-4658.2009.06946.x;
RA   Ulbrichova D., Hrdinka M., Saudek V., Martasek P.;
RT   "Acute intermittent porphyria--impact of mutations found in the
RT   hydroxymethylbilane synthase gene on biochemical and enzymatic protein
RT   properties.";
RL   FEBS J. 276:2106-2115(2009).
RN   [59]
RP   BIOPHYSICOCHEMICAL PROPERTIES, VARIANT ASN-132, CHARACTERIZATION OF
RP   VARIANTS AIP TRP-116; TRP-167; TRP-173 AND GLU-215, AND
RP   CHARACTERIZATION OF VARIANT ASN-132.
RX   PubMed=23815679; DOI=10.1042/BSR20130045;
RA   Bustad H.J., Vorland M., Ronneseth E., Sandberg S., Martinez A.,
RA   Toska K.;
RT   "Conformational stability and activity analysis of two
RT   hydroxymethylbilane synthase mutants, K132N and V215E, with different
RT   phenotypic association with acute intermittent porphyria.";
RL   Biosci. Rep. 33:0-0(2013).
RN   [60]
RP   VARIANTS AIP ARG-111 AND PRO-338.
RX   PubMed=25703257; DOI=10.1111/ahg.12102;
RA   Gonzaga A.D., de Amorim L.M., Fonseca A.B., Nogueira T.L.,
RA   Pereira O.M., Nagai M.A., de Oliveira Barretto O.C., Ribeiro G.S.;
RT   "Hydroxymethylbilane synthase gene mutations and polymorphisms in
RT   Brazilian families with acute intermittent porphyria.";
RL   Ann. Hum. Genet. 79:162-172(2015).
RN   [61]
RP   VARIANT AIP PRO-330.
RX   PubMed=25870942; DOI=10.1016/j.gene.2015.04.027;
RA   Yang J., Wang H., Yin K., Hua B., Zhu T., Zhao Y., Guo S., Yu X.,
RA   Wu W., Zhou Z.;
RT   "A novel mutation in the porphobilinogen deaminase gene in an extended
RT   Chinese family with acute intermittent porphyria.";
RL   Gene 565:288-290(2015).
CC   -!- FUNCTION: Tetrapolymerization of the monopyrrole PBG into the
CC       hydroxymethylbilane pre-uroporphyrinogen in several discrete
CC       steps.
CC   -!- CATALYTIC ACTIVITY: 4 porphobilinogen + H(2)O =
CC       hydroxymethylbilane + 4 NH(3).
CC   -!- COFACTOR:
CC       Name=dipyrromethane; Xref=ChEBI:CHEBI:60342;
CC       Note=Binds 1 dipyrromethane group covalently.;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=48 uM for porphobilinogen {ECO:0000269|PubMed:23815679};
CC         Vmax=1261 nmol/h/mg enzyme (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:23815679};
CC       Temperature dependence:
CC         Displays high thermal stability. The half-denaturation
CC         temperature (Tm) is about 74 degrees Celsius.
CC         {ECO:0000269|PubMed:23815679};
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate:
CC       step 2/4.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Non-erythropoietic;
CC         IsoId=P08397-1; Sequence=Displayed;
CC       Name=2; Synonyms=Erythrocyte;
CC         IsoId=P08397-2; Sequence=VSP_002067;
CC       Name=3;
CC         IsoId=P08397-3; Sequence=VSP_047294;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P08397-4; Sequence=VSP_002067, VSP_047294;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is ubiquitously expressed. Isoform 2
CC       is found only in erythroid cells. {ECO:0000269|PubMed:3422427}.
CC   -!- DISEASE: Acute intermittent porphyria (AIP) [MIM:176000]: A form
CC       of porphyria. Porphyrias are inherited defects in the biosynthesis
CC       of heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. AIP is an
CC       autosomal dominant form of hepatic porphyria characterized by
CC       attacks of gastrointestinal disturbances, abdominal colic, with
CC       neurological dysfunctions, hypertension, tachycardia and
CC       peripheral neuropathy. Most attacks are precipitated by drugs,
CC       alcohol, caloric deprivation, infections, or endocrine factors.
CC       {ECO:0000269|PubMed:10453740, ECO:0000269|PubMed:10494093,
CC       ECO:0000269|PubMed:10502788, ECO:0000269|PubMed:10602775,
CC       ECO:0000269|PubMed:10657149, ECO:0000269|PubMed:10782018,
CC       ECO:0000269|PubMed:11013452, ECO:0000269|PubMed:11030413,
CC       ECO:0000269|PubMed:11399210, ECO:0000269|PubMed:11857754,
CC       ECO:0000269|PubMed:12372055, ECO:0000269|PubMed:12406973,
CC       ECO:0000269|PubMed:12773194, ECO:0000269|PubMed:1301948,
CC       ECO:0000269|PubMed:1427766, ECO:0000269|PubMed:14669009,
CC       ECO:0000269|PubMed:14757946, ECO:0000269|PubMed:1496994,
CC       ECO:0000269|PubMed:14970743, ECO:0000269|PubMed:15669678,
CC       ECO:0000269|PubMed:16211556, ECO:0000269|PubMed:1714233,
CC       ECO:0000269|PubMed:18406650, ECO:0000269|PubMed:19138865,
CC       ECO:0000269|PubMed:19292878, ECO:0000269|PubMed:2243128,
CC       ECO:0000269|PubMed:23815679, ECO:0000269|PubMed:25703257,
CC       ECO:0000269|PubMed:25870942, ECO:0000269|PubMed:7757070,
CC       ECO:0000269|PubMed:7962538, ECO:0000269|PubMed:8081367,
CC       ECO:0000269|PubMed:8262523, ECO:0000269|PubMed:8268934,
CC       ECO:0000269|PubMed:8270254, ECO:0000269|PubMed:8270256,
CC       ECO:0000269|PubMed:8401516, ECO:0000269|PubMed:8825929,
CC       ECO:0000269|PubMed:9199558, ECO:0000269|PubMed:9225970,
CC       ECO:0000269|PubMed:9463797, ECO:0000269|PubMed:9654202,
CC       ECO:0000269|Ref.46}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The porphobilinogen subunits are added to the
CC       dipyrromethane group.
CC   -!- SIMILARITY: Belongs to the HMBS family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04217; CAA27801.1; -; mRNA.
DR   EMBL; X04808; CAA28499.1; -; mRNA.
DR   EMBL; M95623; AAA60029.1; -; Genomic_DNA.
DR   EMBL; M95623; AAA60030.1; -; Genomic_DNA.
DR   EMBL; AK000628; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK131072; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK290275; BAF82964.1; -; mRNA.
DR   EMBL; AP003391; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003392; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67447.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67449.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67450.1; -; Genomic_DNA.
DR   EMBL; BC000520; AAH00520.1; -; mRNA.
DR   EMBL; BC008149; AAH08149.1; -; mRNA.
DR   EMBL; BC019323; AAH19323.1; -; mRNA.
DR   EMBL; X68018; CAA48156.1; -; Genomic_DNA.
DR   EMBL; S60381; AAC60602.1; -; Genomic_DNA.
DR   CCDS; CCDS41726.1; -. [P08397-2]
DR   CCDS; CCDS58186.1; -. [P08397-3]
DR   CCDS; CCDS58187.1; -. [P08397-4]
DR   CCDS; CCDS8409.1; -. [P08397-1]
DR   PIR; A45012; IBHUN.
DR   RefSeq; NP_000181.2; NM_000190.3. [P08397-1]
DR   RefSeq; NP_001019553.1; NM_001024382.1. [P08397-2]
DR   RefSeq; NP_001245137.1; NM_001258208.1. [P08397-3]
DR   RefSeq; NP_001245138.1; NM_001258209.1. [P08397-4]
DR   RefSeq; XP_005271588.1; XM_005271531.1. [P08397-2]
DR   RefSeq; XP_005271589.1; XM_005271532.1. [P08397-2]
DR   RefSeq; XP_016873118.1; XM_017017629.1. [P08397-2]
DR   UniGene; Hs.82609; -.
DR   PDB; 3ECR; X-ray; 2.18 A; A/B=1-361.
DR   PDB; 3EQ1; X-ray; 2.80 A; A/B=1-361.
DR   PDBsum; 3ECR; -.
DR   PDBsum; 3EQ1; -.
DR   ProteinModelPortal; P08397; -.
DR   SMR; P08397; -.
DR   BioGrid; 109388; 12.
DR   IntAct; P08397; 3.
DR   STRING; 9606.ENSP00000278715; -.
DR   BindingDB; P08397; -.
DR   iPTMnet; P08397; -.
DR   PhosphoSitePlus; P08397; -.
DR   BioMuta; HMBS; -.
DR   DMDM; 1170217; -.
DR   EPD; P08397; -.
DR   MaxQB; P08397; -.
DR   PaxDb; P08397; -.
DR   PeptideAtlas; P08397; -.
DR   PRIDE; P08397; -.
DR   DNASU; 3145; -.
DR   Ensembl; ENST00000278715; ENSP00000278715; ENSG00000256269. [P08397-1]
DR   Ensembl; ENST00000392841; ENSP00000376584; ENSG00000256269. [P08397-2]
DR   Ensembl; ENST00000442944; ENSP00000392041; ENSG00000256269. [P08397-2]
DR   Ensembl; ENST00000537841; ENSP00000444730; ENSG00000256269. [P08397-2]
DR   Ensembl; ENST00000542729; ENSP00000443058; ENSG00000256269. [P08397-4]
DR   Ensembl; ENST00000544387; ENSP00000438424; ENSG00000256269. [P08397-3]
DR   Ensembl; ENST00000627066; ENSP00000486176; ENSG00000281702. [P08397-1]
DR   Ensembl; ENST00000627967; ENSP00000487456; ENSG00000281702. [P08397-2]
DR   Ensembl; ENST00000628117; ENSP00000486199; ENSG00000281702. [P08397-2]
DR   Ensembl; ENST00000629150; ENSP00000486742; ENSG00000281702. [P08397-3]
DR   Ensembl; ENST00000630574; ENSP00000486658; ENSG00000281702. [P08397-4]
DR   Ensembl; ENST00000630689; ENSP00000486979; ENSG00000281702. [P08397-2]
DR   GeneID; 3145; -.
DR   KEGG; hsa:3145; -.
DR   UCSC; uc001puz.2; human. [P08397-1]
DR   CTD; 3145; -.
DR   DisGeNET; 3145; -.
DR   GeneCards; HMBS; -.
DR   GeneReviews; HMBS; -.
DR   HGNC; HGNC:4982; HMBS.
DR   HPA; HPA006114; -.
DR   HPA; HPA050659; -.
DR   MalaCards; HMBS; -.
DR   MIM; 176000; phenotype.
DR   MIM; 609806; gene.
DR   neXtProt; NX_P08397; -.
DR   OpenTargets; ENSG00000256269; -.
DR   Orphanet; 79276; Acute intermittent porphyria.
DR   PharmGKB; PA29317; -.
DR   eggNOG; KOG2892; Eukaryota.
DR   eggNOG; COG0181; LUCA.
DR   GeneTree; ENSGT00390000009083; -.
DR   HOGENOM; HOG000228587; -.
DR   HOVERGEN; HBG000967; -.
DR   InParanoid; P08397; -.
DR   KO; K01749; -.
DR   OMA; GAICIES; -.
DR   OrthoDB; EOG091G0B9U; -.
DR   PhylomeDB; P08397; -.
DR   TreeFam; TF105389; -.
DR   BioCyc; MetaCyc:HS07607-MONOMER; -.
DR   BRENDA; 2.5.1.61; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   SABIO-RK; P08397; -.
DR   UniPathway; UPA00251; UER00319.
DR   EvolutionaryTrace; P08397; -.
DR   GeneWiki; Porphobilinogen_deaminase; -.
DR   GenomeRNAi; 3145; -.
DR   PRO; PR:P08397; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000256269; -.
DR   CleanEx; HS_HMBS; -.
DR   ExpressionAtlas; P08397; baseline and differential.
DR   Genevisible; P08397; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004418; F:hydroxymethylbilane synthase activity; IDA:UniProtKB.
DR   GO; GO:0006783; P:heme biosynthetic process; IBA:GO_Central.
DR   GO; GO:0018160; P:peptidyl-pyrromethane cofactor linkage; IEA:InterPro.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   Gene3D; 3.30.160.40; -; 1.
DR   HAMAP; MF_00260; Porphobil_deam; 1.
DR   InterPro; IPR000860; HemC.
DR   InterPro; IPR022419; Porphobilin_deaminase_cofac_BS.
DR   InterPro; IPR022417; Porphobilin_deaminase_N.
DR   InterPro; IPR022418; Porphobilinogen_deaminase_C.
DR   PANTHER; PTHR11557; PTHR11557; 1.
DR   Pfam; PF01379; Porphobil_deam; 1.
DR   Pfam; PF03900; Porphobil_deamC; 1.
DR   PIRSF; PIRSF001438; 4pyrrol_synth_OHMeBilane_synth; 1.
DR   PRINTS; PR00151; PORPHBDMNASE.
DR   SUPFAM; SSF54782; SSF54782; 2.
DR   TIGRFAMs; TIGR00212; hemC; 1.
DR   PROSITE; PS00533; PORPHOBILINOGEN_DEAM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation;
KW   Heme biosynthesis; Phosphoprotein; Porphyrin biosynthesis;
KW   Reference proteome; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    361       Porphobilinogen deaminase.
FT                                /FTId=PRO_0000143034.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES      15     15       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      69     69       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      74     74       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P22907}.
FT   MOD_RES     147    147       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     261    261       S-(dipyrrolylmethanemethyl)cysteine.
FT   VAR_SEQ       1     17       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:2875434}.
FT                                /FTId=VSP_002067.
FT   VAR_SEQ     218    257       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047294.
FT   VARIANT      18     18       M -> I (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025558.
FT   VARIANT      22     22       R -> C (in AIP; dbSNP:rs189159450).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:9463797}.
FT                                /FTId=VAR_003638.
FT   VARIANT      24     24       G -> S (in AIP).
FT                                /FTId=VAR_011001.
FT   VARIANT      26     26       R -> C (in AIP; less than 1% of wild-type
FT                                deaminase activity).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:10657149,
FT                                ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:19292878}.
FT                                /FTId=VAR_011002.
FT   VARIANT      26     26       R -> H (in AIP; severe decrease in
FT                                deaminase activity; dbSNP:rs118204103).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:11857754,
FT                                ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:16211556,
FT                                ECO:0000269|PubMed:19292878,
FT                                ECO:0000269|PubMed:8401516}.
FT                                /FTId=VAR_003639.
FT   VARIANT      28     28       S -> N (in AIP).
FT                                /FTId=VAR_011003.
FT   VARIANT      31     31       A -> P (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011004.
FT   VARIANT      31     31       A -> T (in AIP; dbSNP:rs118204104).
FT                                {ECO:0000269|PubMed:8270254}.
FT                                /FTId=VAR_003640.
FT   VARIANT      32     32       R -> P (in AIP; results in less than 1%
FT                                of wild-type deaminase activity).
FT                                {ECO:0000269|PubMed:19138865}.
FT                                /FTId=VAR_074151.
FT   VARIANT      34     34       Q -> K (in AIP; dbSNP:rs118204105).
FT                                {ECO:0000269|PubMed:1427766}.
FT                                /FTId=VAR_003641.
FT   VARIANT      34     34       Q -> P (in AIP; less than 3% of
FT                                activity). {ECO:0000269|PubMed:10494093}.
FT                                /FTId=VAR_011005.
FT   VARIANT      34     34       Q -> R (in AIP).
FT                                {ECO:0000269|PubMed:14669009}.
FT                                /FTId=VAR_025559.
FT   VARIANT      35     35       T -> M (in AIP).
FT                                {ECO:0000269|PubMed:11013452}.
FT                                /FTId=VAR_011006.
FT   VARIANT      42     42       L -> S (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011007.
FT   VARIANT      55     55       A -> S (in AIP; dbSNP:rs118204106).
FT                                {ECO:0000269|PubMed:8270254}.
FT                                /FTId=VAR_003642.
FT   VARIANT      59     59       T -> I (in AIP; unknown pathological
FT                                significance; has 80% of wild-type
FT                                deaminase activity; dbSNP:rs761004837).
FT                                {ECO:0000269|PubMed:18406650}.
FT                                /FTId=VAR_074152.
FT   VARIANT      61     61       D -> N (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011008.
FT   VARIANT      61     61       D -> Y (in AIP).
FT                                {ECO:0000269|PubMed:11857754}.
FT                                /FTId=VAR_025560.
FT   VARIANT      78     78       T -> P (in AIP).
FT                                {ECO:0000269|PubMed:11399210}.
FT                                /FTId=VAR_025561.
FT   VARIANT      80     80       E -> G (in AIP).
FT                                {ECO:0000269|PubMed:11399210}.
FT                                /FTId=VAR_025562.
FT   VARIANT      81     81       L -> P (in AIP; dbSNP:rs118204119).
FT                                {ECO:0000269|PubMed:14970743}.
FT                                /FTId=VAR_025563.
FT   VARIANT      85     85       L -> R (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011009.
FT   VARIANT      86     86       E -> V (in AIP; dbSNP:rs150763621).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025564.
FT   VARIANT      90     90       V -> G (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011010.
FT   VARIANT      92     92       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025565.
FT   VARIANT      93     93       V -> F (in AIP; loss of activity).
FT                                {ECO:0000269|PubMed:7962538}.
FT                                /FTId=VAR_003643.
FT   VARIANT      93     93       Missing (in AIP).
FT                                {ECO:0000269|PubMed:11857754}.
FT                                /FTId=VAR_025566.
FT   VARIANT      96     96       S -> F (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025567.
FT   VARIANT      98     98       K -> R (in AIP).
FT                                /FTId=VAR_003644.
FT   VARIANT      99     99       D -> G (in AIP; complete loss of
FT                                deaminase activity).
FT                                {ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:12773194}.
FT                                /FTId=VAR_025568.
FT   VARIANT      99     99       D -> H (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025569.
FT   VARIANT      99     99       D -> N (in AIP). {ECO:0000269|Ref.46}.
FT                                /FTId=VAR_025570.
FT   VARIANT     111    111       G -> R (in AIP; dbSNP:rs118204107).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:10494093,
FT                                ECO:0000269|PubMed:10602775,
FT                                ECO:0000269|PubMed:11013452,
FT                                ECO:0000269|PubMed:11399210,
FT                                ECO:0000269|PubMed:11857754,
FT                                ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:15669678,
FT                                ECO:0000269|PubMed:25703257,
FT                                ECO:0000269|PubMed:8268934}.
FT                                /FTId=VAR_003645.
FT   VARIANT     113    113       I -> T (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025571.
FT   VARIANT     116    116       R -> Q (in AIP).
FT                                {ECO:0000269|PubMed:8081367}.
FT                                /FTId=VAR_003646.
FT   VARIANT     116    116       R -> W (in AIP; loss of activity; affects
FT                                protein conformation; lower thermal
FT                                stability than wild-type enzyme;
FT                                dbSNP:rs118204094).
FT                                {ECO:0000269|PubMed:10602775,
FT                                ECO:0000269|PubMed:11030413,
FT                                ECO:0000269|PubMed:23815679,
FT                                ECO:0000269|PubMed:7962538,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003647.
FT   VARIANT     119    119       P -> L (in AIP).
FT                                {ECO:0000269|PubMed:8825929,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003648.
FT   VARIANT     122    122       A -> G (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025572.
FT   VARIANT     124    124       V -> D (in AIP).
FT                                /FTId=VAR_011011.
FT   VARIANT     132    132       K -> N (found in a patient with unclear
FT                                porphyria-related biochemical findings
FT                                and abdominal pain; unknown pathological
FT                                significance; does not affect activity;
FT                                does not affect Vmax; does not affect KM;
FT                                does not affect thermal stability;
FT                                dbSNP:rs551209435).
FT                                {ECO:0000269|PubMed:23815679}.
FT                                /FTId=VAR_073714.
FT   VARIANT     149    149       R -> L (in AIP).
FT                                {ECO:0000269|PubMed:8270254}.
FT                                /FTId=VAR_003649.
FT   VARIANT     149    149       R -> Q (in AIP; loss of deaminase
FT                                activity; dbSNP:rs118204098).
FT                                {ECO:0000269|PubMed:12773194,
FT                                ECO:0000269|PubMed:1714233}.
FT                                /FTId=VAR_003650.
FT   VARIANT     152    152       Missing (in AIP).
FT                                {ECO:0000269|PubMed:10502788}.
FT                                /FTId=VAR_009223.
FT   VARIANT     167    167       R -> Q (in AIP; decreased deaminase
FT                                activity due to defective enzyme-
FT                                intermediate complexes turnover and
FT                                regeneration of free enzyme molecules;
FT                                dbSNP:rs118204095).
FT                                {ECO:0000269|PubMed:12773194,
FT                                ECO:0000269|PubMed:1427766,
FT                                ECO:0000269|PubMed:2243128,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003651.
FT   VARIANT     167    167       R -> W (in AIP; results in less than 5%
FT                                of wild-type activity; 2-fold decrease of
FT                                Vmax; 33-fold increase of KM;
FT                                dbSNP:rs118204101).
FT                                {ECO:0000269|PubMed:10602775,
FT                                ECO:0000269|PubMed:1301948,
FT                                ECO:0000269|PubMed:1496994,
FT                                ECO:0000269|PubMed:23815679,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003652.
FT   VARIANT     173    173       R -> Q (in AIP; less than 1% of wild-type
FT                                activity; dbSNP:rs118204096).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:11857754,
FT                                ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:12773194,
FT                                ECO:0000269|PubMed:1301948,
FT                                ECO:0000269|PubMed:15669678,
FT                                ECO:0000269|PubMed:19292878,
FT                                ECO:0000269|PubMed:2243128}.
FT                                /FTId=VAR_003653.
FT   VARIANT     173    173       R -> W (in AIP; 1% of wild-type activity;
FT                                lower thermal stability than wild-type
FT                                enzyme; dbSNP:rs575222284).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:10494093,
FT                                ECO:0000269|PubMed:10602775,
FT                                ECO:0000269|PubMed:11399210,
FT                                ECO:0000269|PubMed:16211556,
FT                                ECO:0000269|PubMed:23815679,
FT                                ECO:0000269|PubMed:8081367,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003654.
FT   VARIANT     177    177       L -> R (in AIP; dbSNP:rs118204108).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:1427766,
FT                                ECO:0000269|PubMed:8081367}.
FT                                /FTId=VAR_003655.
FT   VARIANT     178    178       D -> N (in AIP; unknown pathological
FT                                significance; has 80% of wild-type
FT                                deaminase activity; dbSNP:rs536814318).
FT                                {ECO:0000269|PubMed:12372055,
FT                                ECO:0000269|PubMed:19138865}.
FT                                /FTId=VAR_011012.
FT   VARIANT     195    195       R -> C (in AIP; severe decrease of
FT                                deaminase activity; dbSNP:rs34413634).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:16211556}.
FT                                /FTId=VAR_003656.
FT   VARIANT     201    201       R -> W (in AIP; residual activity;
FT                                dbSNP:rs118204109).
FT                                {ECO:0000269|PubMed:10494093,
FT                                ECO:0000269|PubMed:7962538,
FT                                ECO:0000269|PubMed:8270256,
FT                                ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_003657.
FT   VARIANT     202    202       V -> L (in AIP).
FT                                {ECO:0000269|PubMed:10657149}.
FT                                /FTId=VAR_011013.
FT   VARIANT     204    204       Q -> K (in AIP; 46% wild-type deaminase
FT                                activity; decreased enzyme stability).
FT                                {ECO:0000269|PubMed:19292878}.
FT                                /FTId=VAR_074153.
FT   VARIANT     209    209       E -> K (in AIP).
FT                                /FTId=VAR_011014.
FT   VARIANT     212    212       M -> V (in AIP; <2% residual activity;
FT                                dbSNP:rs772471000).
FT                                {ECO:0000269|PubMed:10602775}.
FT                                /FTId=VAR_025573.
FT   VARIANT     215    215       V -> E (in AIP; unknown pathological
FT                                significance; results in 30% of wild-type
FT                                activity; 3-fold decrease of Vmax; normal
FT                                KM; affects protein conformation).
FT                                {ECO:0000269|PubMed:14757946,
FT                                ECO:0000269|PubMed:23815679}.
FT                                /FTId=VAR_073715.
FT   VARIANT     215    215       V -> M (in AIP; 19% of wild-type
FT                                deaminase activity).
FT                                {ECO:0000269|PubMed:18406650}.
FT                                /FTId=VAR_074154.
FT   VARIANT     216    216       G -> D (in AIP; dbSNP:rs118204116).
FT                                {ECO:0000269|PubMed:9225970}.
FT                                /FTId=VAR_011015.
FT   VARIANT     217    217       Q -> H (in AIP).
FT                                /FTId=VAR_011016.
FT   VARIANT     217    217       Q -> L (in AIP).
FT                                {ECO:0000269|PubMed:10782018}.
FT                                /FTId=VAR_011017.
FT   VARIANT     219    219       A -> D (in AIP).
FT                                {ECO:0000269|PubMed:10453740}.
FT                                /FTId=VAR_011018.
FT   VARIANT     222    222       V -> M (in AIP).
FT                                {ECO:0000269|PubMed:9654202}.
FT                                /FTId=VAR_003658.
FT   VARIANT     223    223       E -> K (in AIP; dbSNP:rs118204110).
FT                                {ECO:0000269|PubMed:8270254}.
FT                                /FTId=VAR_003659.
FT   VARIANT     225    225       R -> G (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_003660.
FT   VARIANT     225    225       R -> Q (in AIP; dbSNP:rs142459647).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025574.
FT   VARIANT     236    236       G -> S (in AIP).
FT                                {ECO:0000269|PubMed:14669009}.
FT                                /FTId=VAR_025575.
FT   VARIANT     238    238       L -> P (in AIP; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:14757946}.
FT                                /FTId=VAR_073716.
FT   VARIANT     238    238       L -> R (in AIP).
FT                                /FTId=VAR_003661.
FT   VARIANT     244    244       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:14669009}.
FT                                /FTId=VAR_025576.
FT   VARIANT     245    245       L -> R (in AIP; dbSNP:rs118204099).
FT                                {ECO:0000269|PubMed:1714233}.
FT                                /FTId=VAR_003662.
FT   VARIANT     247    247       C -> F (in AIP; residual activity).
FT                                {ECO:0000269|PubMed:7962538}.
FT                                /FTId=VAR_003663.
FT   VARIANT     247    247       C -> R (in AIP; severe decrease of
FT                                deaminase activity; dbSNP:rs118204111).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:16211556,
FT                                ECO:0000269|PubMed:8262523}.
FT                                /FTId=VAR_003664.
FT   VARIANT     248    248       I -> IETLLRCI (in AIP).
FT                                /FTId=VAR_011019.
FT   VARIANT     250    250       E -> A (in AIP; severe decrease of
FT                                deaminase activity).
FT                                {ECO:0000269|PubMed:16211556,
FT                                ECO:0000269|PubMed:8825929}.
FT                                /FTId=VAR_003665.
FT   VARIANT     250    250       E -> D (in AIP; less than 1% of wild-type
FT                                deaminase activity).
FT                                {ECO:0000269|PubMed:19292878}.
FT                                /FTId=VAR_074155.
FT   VARIANT     250    250       E -> K (in AIP; dbSNP:rs118204112).
FT                                {ECO:0000269|PubMed:8270254}.
FT                                /FTId=VAR_003666.
FT   VARIANT     250    250       E -> Q (in AIP).
FT                                /FTId=VAR_011020.
FT   VARIANT     250    250       E -> V (in AIP).
FT                                /FTId=VAR_011021.
FT   VARIANT     252    252       A -> T (in AIP; dbSNP:rs118204113).
FT                                {ECO:0000269|PubMed:8262523}.
FT                                /FTId=VAR_003667.
FT   VARIANT     252    252       A -> V (in AIP; dbSNP:rs118204114).
FT                                {ECO:0000269|PubMed:8262523}.
FT                                /FTId=VAR_003668.
FT   VARIANT     254    254       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025577.
FT   VARIANT     256    256       H -> N (in AIP; dbSNP:rs118204115).
FT                                {ECO:0000269|PubMed:1427766}.
FT                                /FTId=VAR_003669.
FT   VARIANT     256    256       H -> Y (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_011022.
FT   VARIANT     260    260       G -> D (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025578.
FT   VARIANT     261    261       C -> Y (in AIP).
FT                                {ECO:0000269|PubMed:12406973}.
FT                                /FTId=VAR_025579.
FT   VARIANT     267    267       V -> M (in AIP).
FT                                /FTId=VAR_011023.
FT   VARIANT     269    269       T -> I (in AIP).
FT                                {ECO:0000269|PubMed:10453740,
FT                                ECO:0000269|PubMed:8081367}.
FT                                /FTId=VAR_003670.
FT   VARIANT     270    270       A -> D (in AIP).
FT                                /FTId=VAR_011024.
FT   VARIANT     270    270       A -> G (in AIP).
FT                                {ECO:0000269|PubMed:11030413}.
FT                                /FTId=VAR_011025.
FT   VARIANT     274    274       G -> R (in AIP).
FT                                {ECO:0000269|PubMed:8081367}.
FT                                /FTId=VAR_003671.
FT   VARIANT     278    278       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:9654202}.
FT                                /FTId=VAR_003672.
FT   VARIANT     280    280       G -> R (in AIP).
FT                                /FTId=VAR_003673.
FT   VARIANT     281    281       Missing (in AIP).
FT                                {ECO:0000269|PubMed:11013452}.
FT                                /FTId=VAR_011026.
FT   VARIANT     329    332       Missing (in AIP).
FT                                {ECO:0000269|PubMed:10494093}.
FT                                /FTId=VAR_011027.
FT   VARIANT     330    330       A -> P (in AIP).
FT                                {ECO:0000269|PubMed:25870942}.
FT                                /FTId=VAR_074156.
FT   VARIANT     335    335       G -> D (in AIP).
FT                                {ECO:0000269|PubMed:11857754}.
FT                                /FTId=VAR_011028.
FT   VARIANT     335    335       G -> S (in AIP; less than 3% of
FT                                activity). {ECO:0000269|PubMed:10494093}.
FT                                /FTId=VAR_011029.
FT   VARIANT     338    338       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:25703257}.
FT                                /FTId=VAR_074157.
FT   VARIANT     343    343       L -> P (in AIP).
FT                                {ECO:0000269|PubMed:12372055}.
FT                                /FTId=VAR_025580.
FT   CONFLICT    177    177       L -> M (in Ref. 3; AAA60029/AAA60030).
FT                                {ECO:0000305}.
FT   CONFLICT    210    210       E -> K (in Ref. 2; CAA28499).
FT                                {ECO:0000305}.
FT   CONFLICT    349    349       N -> T (in Ref. 1; CAA27801).
FT                                {ECO:0000305}.
FT   STRAND       20     28       {ECO:0000244|PDB:3ECR}.
FT   HELIX        29     45       {ECO:0000244|PDB:3ECR}.
FT   STRAND       49     56       {ECO:0000244|PDB:3ECR}.
FT   HELIX        78     86       {ECO:0000244|PDB:3ECR}.
FT   STRAND       91     96       {ECO:0000244|PDB:3ECR}.
FT   HELIX        97     99       {ECO:0000244|PDB:3ECR}.
FT   STRAND      108    113       {ECO:0000244|PDB:3ECR}.
FT   STRAND      121    125       {ECO:0000244|PDB:3ECR}.
FT   HELIX       127    129       {ECO:0000244|PDB:3EQ1}.
FT   TURN        134    136       {ECO:0000244|PDB:3ECR}.
FT   STRAND      142    144       {ECO:0000244|PDB:3ECR}.
FT   HELIX       148    157       {ECO:0000244|PDB:3ECR}.
FT   STRAND      161    164       {ECO:0000244|PDB:3ECR}.
FT   HELIX       170    179       {ECO:0000244|PDB:3ECR}.
FT   STRAND      180    182       {ECO:0000244|PDB:3ECR}.
FT   STRAND      184    189       {ECO:0000244|PDB:3ECR}.
FT   HELIX       190    195       {ECO:0000244|PDB:3ECR}.
FT   HELIX       199    201       {ECO:0000244|PDB:3ECR}.
FT   TURN        208    210       {ECO:0000244|PDB:3ECR}.
FT   TURN        215    218       {ECO:0000244|PDB:3ECR}.
FT   STRAND      220    225       {ECO:0000244|PDB:3ECR}.
FT   HELIX       229    236       {ECO:0000244|PDB:3ECR}.
FT   HELIX       241    257       {ECO:0000244|PDB:3ECR}.
FT   STRAND      263    272       {ECO:0000244|PDB:3ECR}.
FT   STRAND      275    283       {ECO:0000244|PDB:3ECR}.
FT   STRAND      289    298       {ECO:0000244|PDB:3ECR}.
FT   HELIX       325    344       {ECO:0000244|PDB:3ECR}.
FT   HELIX       347    353       {ECO:0000244|PDB:3ECR}.
SQ   SEQUENCE   361 AA;  39330 MW;  8F2F6F4150F1AD7E CRC64;
     MSGNGNAAAT AEENSPKMRV IRVGTRKSQL ARIQTDSVVA TLKASYPGLQ FEIIAMSTTG
     DKILDTALSK IGEKSLFTKE LEHALEKNEV DLVVHSLKDL PTVLPPGFTI GAICKRENPH
     DAVVFHPKFV GKTLETLPEK SVVGTSSLRR AAQLQRKFPH LEFRSIRGNL NTRLRKLDEQ
     QEFSAIILAT AGLQRMGWHN RVGQILHPEE CMYAVGQGAL GVEVRAKDQD ILDLVGVLHD
     PETLLRCIAE RAFLRHLEGG CSVPVAVHTA MKDGQLYLTG GVWSLDGSDS IQETMQATIH
     VPAQHEDGPE DDPQLVGITA RNIPRGPQLA AQNLGISLAN LLLSKGAKNI LDVARQLNDA
     H
//
